Skip to main content
Premium Trial:

Request an Annual Quote

Switch for the Second

France is to announce that individuals under the age of 55 who have received their first dose of AstraZeneca's SARS-CoV-2 vaccine should receive one of the mRNA-based vaccines for their second dose, Reuters reports.

AstraZeneca has run into issues of transparency in its analyses and with reports of side effects with its vaccine. A number of countries, mostly in Europe, paused their rollout of AstraZeneca's vaccine following reports of a rare blood clot side effect. The European Medicines Agency announced, though, that the vaccine is safe and effective and that its benefits outweigh any potential risks, which led some countries to resume administering it.

Some countries like France, though, have advised that the vaccine only be administered to people over the age of 55, Reuters says, noting that the blood clot side effect has mostly occurred in young people. It adds that France is now following in Germany's footsteps to advise that people under 55 who have received one dose of AstraZeneca's SARS-CoV-2 vaccine should receive a different, mRNA-based vaccine for their second dose.

This decision, Reuters notes, is "significant" as mixing and matching of vaccines has not been tested in late-stage clinical trials.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.